BridgeBio Pharma (FRA:2CL) Accounts Payable & Accrued Expense : €88.3 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Accounts Payable & Accrued Expense?

BridgeBio Pharma's quarterly accounts payable & accrued expense increased from Sep. 2024 (€71.5 Mil) to Dec. 2024 (€73.5 Mil) and increased from Dec. 2024 (€73.5 Mil) to Mar. 2025 (€88.3 Mil).

BridgeBio Pharma's annual accounts payable & accrued expense declined from Dec. 2022 (€74.0 Mil) to Dec. 2023 (€69.9 Mil) but then increased from Dec. 2023 (€69.9 Mil) to Dec. 2024 (€73.5 Mil).

BridgeBio Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for BridgeBio Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Accounts Payable & Accrued Expense Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

45.34

82.39

73.95

69.92

73.50

BridgeBio Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															83.34	79.51	71.45	73.50	88.31

BridgeBio Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

BBIO:USA 1BBIO:Italy

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines